Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials
Published:April 15, 2021
DOI: https://doi.org/10.1016/S2213-8587(21)00056-5
The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 5, May 2021, Pages e1937–e1952,
https://doi.org/10.1210/clinem/dgaa982
The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 5, May 2021, Pages 1325–1332, https://doi.org/10.1210/clinem/dgab070
Published: 09 February 2021
Context/objective
The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD).
Methods
Matteo Spaziani, Chiara Tarantino, Natascia Tahani, Daniele Gianfrilli, Emilia Sbardella, Andrea M Isidori, Andrea Lenzi, Antonio F Radicioni
Frontiers in Endocrinology 2021, 12: 634288
Best Pract Res Clin Endocrinol Metab. 2021 Feb 6;101491.
PMID: 33593680
Published Online:23 Dec 2020
https://doi.org/10.1089/thy.2020.0555
Background: Refining the risk of malignancy in patients presenting with thyroid nodules with indeterminate cytology (IC) is a critical challenge. We investigated the performances of 18F-fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) to predict malignancy.